Compare Phillips 66 (PSX) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Phillips 66 vs 10X Genomics Inc — how do they compare? Phillips 66 trades at $281.02 (market cap $108.38B), while 10X Genomics Inc trades at $80.1 (market cap $9.92B). The key difference: Phillips 66 is far larger — about 10.9× 10X Genomics Inc's market cap, and Phillips 66 pays a 1.87% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Phillips 66 for 62 Days and 10X Genomics Inc for 92 Days on average.
| PSX | TXG | |
|---|---|---|
Market Cap | $108.38B | $9.92B |
Volume | 1,841,742 | 9,372,166 |
Sector | Energy | Health |
52-Week High | $281.60 | $97.74 |
52-Week Low | $126.76 | $11.48 |
Typical Hold Time | 62 Days | 92 Days |
Enterprise Value | $124.85B | $9.44B |
Dividend Yield | 1.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PSX trades at $281.60, up 4.38% today, near its 52-week high. The stock shows bullish technical momentum with strong moving average support. Fundamentally, the company has beaten earnings estimates for three consecutive quarters, with a P/E of 15.5 and robust ROE of 24.02%. Recent news highlights structural strength in refining margins and AI-driven operational improvements.
Outlook remains positive with analyst consensus at Buy (57% of ratings) and a $279 price target. Key opportunities include sustained refining profitability and debt reduction. Risks involve volatile energy markets and potential policy impacts on diesel exports. Cash flow is projected to rebound to $3.0B in 2026.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
